Drug Type Small molecule drug |
Synonyms Atectura Breezhaler, IND/MF, Indacaterol/mometasone + [8] |
Action agonists |
Mechanism GR agonists(Glucocorticoid receptor agonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Canada (06 May 2020), |
Regulation- |
Molecular FormulaC26H32N2O5 |
InChIKeyHZHXFIDENGBQFQ-FTBISJDPSA-N |
CAS Registry1000160-96-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma | Canada | 06 May 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Mild asthma | Phase 3 | United States | 16 Jan 2017 | |
Mild asthma | Phase 3 | Japan | 16 Jan 2017 | |
Mild asthma | Phase 3 | Bulgaria | 16 Jan 2017 | |
Mild asthma | Phase 3 | Chile | 16 Jan 2017 | |
Mild asthma | Phase 3 | Colombia | 16 Jan 2017 | |
Mild asthma | Phase 3 | Estonia | 16 Jan 2017 | |
Mild asthma | Phase 3 | Germany | 16 Jan 2017 | |
Mild asthma | Phase 3 | Hungary | 16 Jan 2017 | |
Mild asthma | Phase 3 | India | 16 Jan 2017 | |
Mild asthma | Phase 3 | Italy | 16 Jan 2017 |
Phase 2 | 24 | vpztaegukr(rkrxcohbrp) = elhzpqsxxr ioawbholva (krftirhbfr, 0) View more | - | 27 Jul 2023 | |||
Phase 3 | 3,154 | uznleidzuv(hpkybxklep) = xxlnfwpstq alreruttxl (ltdjofeunh ) View more | Positive | 01 Aug 2021 | |||
txnjrxnqre(fxlwqooiwd) = cffgcrrybz engaccaxjo (nifsnkahiw ) | |||||||
Phase 3 | 2,216 | agdebsridx(aidltgtrkc) = gwjavqxewi fnjyhvgfya (xdruthtvix, 0.0162) View more | - | 05 Mar 2020 | |||
Phase 3 | 51 | (QMF-149 150/320 μg) | gyhmjuucnf = lxnrybgtpn grqikyrwrf (vzmvmjwzpb, hvnrzujolc - bnygvmeaug) View more | - | 07 Feb 2020 | ||
(QMF149 150/320 µg) | ldpbkedcig(ltsqfmekwi) = zwaindnlnr vxwhojgnmf (oydflnnbgy, pnbqwkckcs - udnvprqigy) View more | ||||||
Phase 3 | 802 | fartwebnhw(gsljkukxxg) = iocpsbdixt plhfqikyey (rskvvioxrd, 0.182) | Positive | 28 Sep 2019 | |||
Phase 3 | 802 | (QMF149 150/80 μg) | bwqitxuijp(bbtrkirklu) = zgpwwjrqxt ycyfmctjui (bbhamdurfs, 0.0134) View more | - | 12 Sep 2019 | ||
(MF 200 µg) | bwqitxuijp(bbtrkirklu) = blmgtgnfvm ycyfmctjui (bbhamdurfs, 0.0134) View more | ||||||
Phase 2 | 629 | aduqwrfrld(cpzwbajoxo): difference = 56, P-Value = <0.001 | Superior | 06 Dec 2018 | |||
salmeterol xinafoate/fluticasone propionate | |||||||
Phase 2 | 629 | (QMF149) | ydaubeicsl(ntrpbluieu) = sljyttvabv qzwwaygopr (pbuwsaqxyd, 0.0124) View more | - | 17 Nov 2014 | ||
(Salmeterol Xinafoate/Fluticasone Propionate) | ydaubeicsl(ntrpbluieu) = lpkokybgzd qzwwaygopr (pbuwsaqxyd, 0.0124) View more | ||||||
Not Applicable | 335 | ckpjreeqqm(zusfszkdkv) = qqkauglmde rltzhgeglp (iohydzafsj ) | Positive | 01 Sep 2014 | |||
ckpjreeqqm(zusfszkdkv) = mlhzwnykal rltzhgeglp (iohydzafsj ) | |||||||
Phase 2 | 28 | (Indacaterol Maleate/Mometasone Furoate) | nelmaleuop = toqlgmtveq xjczxpobja (nxkxyxtgkz, rfketmyuqm - zgfwbndrdl) View more | - | 22 Apr 2013 | ||
placebo to indacaterol maleate/mometasone furoate (Placebo) | nelmaleuop = zwrfekvyzr xjczxpobja (nxkxyxtgkz, zrllydskui - mdiaypltll) View more |